Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan
OBJECTIVE: To investigate the risk factors for unfavourable treatment outcomes among rifampicin-resistant (RR)/MDR-TB patients.
DESIGN: Retrospective medical chart review of RR/MDR-TB patients enrolled for treatment in 2012–2013.
RESULTS: Of 601 RR/MDR-TB patients, 58 (9.7%) had pre-extensively drug-resistant TB (pre-XDR-TB; i.e., MDR-TB with additional resistance to a fluoroquinolone or second-line injectable agent) and 45 (8%) had XDR-TB (MDR-TB with additional resistance to both). Treatment failure and death were reported in respectively 40 (7%) and 89 (15%) cases; 60 (10%) patients were lost to follow-up (LTFU). In multivariable analysis, treatment failure was associated with pre-XDR-TB (adjusted odds ratio [aOR] 3.67, 95%CI 1.47–9.18) or XDR-TB (aOR 8.61, 95%CI 3.48–21.34). Death was associated with age >45 years vs. <25 years (aOR 3.47, 95%CI 1.68–7.19) and no record of any adverse event during treatment (aOR 2.55, 95%CI 1.48–4.39). Changing place of residence during treatment was an independent predictor of LTFU (aOR 4.61, 95%CI 2.41–8.8).
CONCLUSIONS: Our findings highlight the need for 1) the use of regimens with new anti-tuberculosis drugs; 2) good handover of TB patients and 3) effective tracing mechanisms if patients change a place of residence to prevent LTFU.
Document Type: Research Article
Affiliations: 1: KNCV Tuberculosis Foundation, Country Office, Dushanbe 2: USAID TB Control Project, Dushanbe 3: National Centre of Population Protection from Tuberculosis, Dushanbe, Tajikistan 4: Technical Division, Team Evidence, KNCV Tuberculosis Foundation, The Hague, The Netherlands 5: Technical Division, Team Evidence, KNCV Tuberculosis Foundation, The Hague, The Netherlands, Department of Public Health, Epidemiology, and Biostatistics, David Tvildiani Medical University, Tbilisi, Georgia
Publication date: March 1, 2019
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites